Stem Cell Clinic

DiscGenics Announces US Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review – PRNewswire

The DSMC completed a third and final planned mid-trial safety review following treatment of the first six subjects in the high dose study cohort, each of whom was treated based on random assignment into one of three arms: high dose IDCT study treatment, vehicle or placebo.

The DSMC reported there were no safety issues and recommended that the study proceed with completion of patient enrollment with no changes to the protocol.

This news closely follows a recent company announcement that the second planned safety review of the first 30-subject low dose study cohort revealed no safety issues.

"We are delighted to commence the final enrollment stage in our U.S. study of IDCT for DDD and are thrilled that the first 36 patients have now been safely treated," said Flagg Flanagan, Chief Executive Officer and Chairman of the Board of Directors for DiscGenics. "This is a blinded, first-in-human study where neither the treating clinicians nor the patients know what treatment is being administered. As a result, performance of periodic safety checks by an unblinded and independent body was essential to ensuring the ongoing safety of IDCT in a clinical setting. The members of the DSMC played a critical role in this process and we would like to sincerely thank them for their time and thoughtful review of the blinded safety data."

Patient enrollment in this U.S. study will now continue through completion of 60 total subjects.

About the IDCT TrialThe IDCT trial is a prospective, randomized, double-blinded, vehicle- and placebo-controlled, multicenter clinical study to evaluate the safety and preliminary efficacy of IDCT in subjects with single-level, symptomatic lumbar intervertebral disc degeneration. The trial is underway in 14 centers across 12 states in the U.S. and will enroll 60 subjects. Those subjects who meet all eligibility criteria are being randomized to one of four treatment cohorts: low dose IDCT (n=20), high dose IDCT (n=20), vehicle (n=10) and placebo (n=10). Each subject receives a single intradiscal injection of his or her assigned treatment into the target symptomatic lumbar intervertebral disc. Following treatment, subjects will be observed and evaluated for a period of one year, with a one-year extension period. Primary outcome measures include safety and reduction in pain. Secondary outcome measures include reduction in disability and radiographic improvement.

Through this study, IDCT is being evaluated under an investigational new drug (IND) allowanceby the U.S. Food and Drug Administration (FDA) and will be regulated as a drug-biologic through a therapeutics biologics license application (BLA). Importantly, DiscGenics announced in August 2019that the FDA granted Fast Track designation for IDCT as a potential treatment option for chronic low back pain. For more information on the U.S. study, please visit: https://clinicaltrials.gov/ct2/show/NCT03347708.

IDCT is also being evaluated in a multicenter safety study in Japan, which is supported by a Clinical Trial Notification (CTN) approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). For more information on the Japanese study, please visit: https://clinicaltrials.gov/ct2/show/NCT03955315.

About DiscGenicsDiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics believes it has a unique opportunity to harness the restorative potential of the human body to heal millions of patients suffering from the debilitating effects of back pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue, known as Discogenic Cells, to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease. For more information, visit discgenics.com.

Media ContactLindsey Saxonlindsey@discgenics.com

SOURCE DiscGenics, Inc.

http://www.discgenics.com

Read the original post:
DiscGenics Announces US Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review - PRNewswire

Medicare Coverage of CAR-T Cell Therapy Raises New Questions – The Heartland Institute

Still to be determined is how hospitals and other health care facilities will be reimbursed for the therapy and whether patients will have access to the therapy under health care proposals such as Medicare for All or a so-called public option.

One of the most promising cancer treatments to come along in years, CAR-T cell therapy uses the bodys own immune system to attack and kill cancer cells. The treatment involves bioengineering T cells, a white blood cell that fights foreign substances in the body, and equipping them with new Chimeric Antigen Receptors that target cancer cells.

CAR-T cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for children with leukemia and adults with advanced lymphoma. The therapy is typically used alongside other, more traditional treatments such as surgery, chemotherapy, and radiation. Its use in combatting other forms of cancer is pending with the FDA, an agency known for its slow approval process.

Hefty Price Tag

There are currently two approved CAR-T treatments: Novartis Kymriah (tisagenlecleucel) and Gileads Yescarta (axicabtagene).

Like most newly introduced cutting-edge treatments, the two products come with a hefty price tag. A course of treatment of Kymriah costs $475,000 for pediatric and young adult patients with leukemia, and both are priced at $373,000 to treat lymphoma in adults, according tobiopharma.com. Under Centers for Medicare & Medicaid Services (CMS) regulations published in August, Medicare will reimburse hospitals for 65 percent of the treatments cost, or about $242,000, through Part B.

Although hospitals will likely welcome Medicares financial commitment, there still remains a sizable gap. Further complicating reimbursement is the lack of a separate Medicare billing code for CAR-T treatment, which will be handled via codes for bone marrow and stem cell transplants until a CAR-T billing code is developed, which could take up to three years.

CMS worked closely with the FDA and the National Cancer Institute in developing the new regulations, a time-consuming process rooted in the complexities of developing a reimbursement scheme and overseeing an innovative and evolving therapy.

At a July 31 Heritage Foundation panel discussion on Medicare for All, CMS Administrator Seema Verma discussed the challenges government programs face in approving innovative treatments.

Much of the problem is when Congress says you can cover durable medical treatment, supplies, and drugs, said Verma. Sounded great when they wrote that law 30 to 40 years ago but doesnt make sense in todays environment. All of these new treatments are coming out, and they dont fit nicely into the way the law has been constructed, and it creates problems for the agency.

Bonner R. Cohen,Ph.D.,(bcohen@nationalcenter.org)is a senior fellow at the National Center for Public Policy Research and a senior policy analyst with the Committee for a Constructive Tomorrow (CFACT).

More:
Medicare Coverage of CAR-T Cell Therapy Raises New Questions - The Heartland Institute

News – Michigan’s CON Board Sidelines Promising Cancer Treatment – The Heartland Institute

The commission adopted the rule at the behest of several of Michigans established cancer treatment providers and on the advice of a panel of clinical experts it appointed to evaluate the need for the regulation.

The panel also recommended requiring providers to be accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), a national nonprofit organization that inspects cellular therapy facilities.

Keeping Out Competition

CON laws, which in some states are called Certificate of Public Need laws, are designed to keep health care providers from engaging in unnecessary capital outlays that would ultimately be passed on to patients in the form of higher costs. In practice, this means hospitals and other health care providers must get the approval of a state agency before offering new services, expanding their operations, or implementing new medical technologies. Dominant providers frequently use CON laws to limit competition from smaller hospitals.

CAR-T therapy is different from most health care services, states Anna Parsons, a policy coordinator with the American Legislative Exchange Council, because it does not require a capital investment (see commentary).

An FDA-certified hospital should be capable of offering these treatments, since all the high-tech bioengineering is done at other locations, Parsons told Reason.com.

Michigan As Outlier

Michigan state Sen. Curt VanderWall (R-Ludington), who chairs the Senate Health Policy and Human Services Committee, says he opposes CON regulation of CAR-T.

It is concerning to me that the CON commission expanded a requirement into a new clinical service area that goes well beyond the federal requirement, VanderWall toldHealth Care News.

The Centers for Medicare and Medicaid Services makes no mention of FACT accreditation in its August 7 press release stating Medicare will cover the proceedurein healthcare facilities enrolled in the FDA risk evaluation and mitigation strategies for FDA-approved indications.

The new CON requirement to obtain third-party accreditation will be a barrier to access, create an unnecessary financial burden for providers, and limit the sites of care from offering cellular therapies to patients, said VanderWall.

VanderWall says patients should be allowed to choose their own CAR-T provider.

Patient choice and access are priorities for me, said VanderWall. Patients will be able to work with their doctors to find the best treatment site based on safety and access.

Michigan should not be an outlier, VanderWall said. No other state has a CON standard for immune effector cell therapy (IECT), and safe treatment will be offered according to the established federal guidelines in the other 49 states.

A Joint Legislative Committee and the governor were allowed 45 days from the September 19 decision to review the new language to regulate IECT, of which CAR-T is a form, and the FACT accreditation requirement.

AnneMarie Schieber(amschieber@heartland.org)is managing editor ofHealth Care News.

Official Connections:

Michigan State Senator Curt VanderWall, (R Ludington):https://www.senatorcurtvanderwall.com

Link:
News - Michigan's CON Board Sidelines Promising Cancer Treatment - The Heartland Institute

Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare – Business Wire

MCLEAN, Va.--(BUSINESS WIRE)--The Thought Leadership & Innovation Foundation (TLI) announces today plans to build on its existing Regenerative Medicine Program through a research collaboration with cellular therapy industry leader RenovaCare. As part of TLIs efforts to conduct vital research in regenerative medicine and chronic disease, this initiative aims to innovate methods for reducing complications from burn and diabetic wounds across large populations.

Our research base, collaborative institutions and long history of innovation align with RenovaCares commitment to breakthrough biomedical technologies, says Bill Oldham, founder and chairman of the Board, TLI. The patented RenovaCare SkinGun technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies. Working together, our overall goal is to improve the quality, efficiency and effectiveness of patient care by not only developing new treatment methods, but also by making thoughtful and systematic changes to healthcare and health systems.

TLIs Regenerative Medicine program seeks to adapt new strategies based upon sound scientific evidence, utilizing its infrastructure to support the continuation of scientific and medical work, as well as the development of grant-funded research and other initiatives.

Dr. Robin A. Robinson, who is a TLI Fellow, Vice President of Scientific Affairs, RenovaCare, and named one of the top 100 innovators in medicine by Medicine Maker in 2018, states, This exciting collaboration between RenovaCare and TLIs Regenerative Medicine Program is the first step toward the development of meaningful and quality therapeutic treatments that will benefit patients around the world.

About TLI Foundation:

TLI Foundation is a nonprofit foundation focused on driving innovative thinking and action on global issues relating to health, education and economic empowerment. The organization is committed to fostering transformative change and improving the health and well-being outcomes of communities around the world. Visit https://www.thoughtfoundation.org/

About RenovaCare:

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Initial products under development target the bodys largest organ, the skin. Investigative clinical use of their flagship technology has shown to be promising new alternatives for patients suffering from burns, and chronic and acute wounds. https://www.renovacareinc.com.

Follow this link:
Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare - Business Wire

Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy – Seeking Alpha

The recent approval of various gene therapies, for example, Luxturna and Zolgesma and high premium acquisitions of gene therapy companies have shifted the investor focus to this rapidly growing biotechnology field. In this series of review articles, I will review the gene therapy and gene editing field, starting first with the basics, including a brief overview of the history of the field and then moving on to some technical aspects, for example, the manufacturing, different methods of delivery, and then moving on to discussing the competitive landscape covering one genetic disease in each article.

Let's first define what is a gene? A gene is a sequence of nucleotides in DNA that encodes the synthesis of a gene product, which is usually a protein.

(F8 gene, mutations in the gene cause Hemophilia A)

Usually, the code (in the form of a specific arrangement of nucleotides or base pairs contained in the gene is used to form mRNA (called transcription) which acts as a messenger to take the code to the target organ of the body. The information stored in the mRNA is then used to encode and synthesize the target protein (called translation) which then performs its intended function in the body.

(Steps involved in synthesizing a protein from the code in a gene)

An estimated number of protein-coding genes in the human body is approximately 20,000 to 25,000, which has been revised down from the initial prediction of 100,000 genes. Each gene contains a number of base pairs, the number of which is estimated to range from about 50 million to 300 million in the human body. In general, a gene therapy can be broadly defined as delivering in a new gene into the cells to compensate for a defective gene. In gene therapy, a newly delivered gene can perform different functions; for example, it can either replace the defective gene or it can silence an abnormal gene.

(An example of a gene therapy using an adenoviral vector to deliver the normal gene)

While I will discuss the various steps and delivery systems in gene therapy in detail later, viruses like lentiviruses and adenovirus are most commonly used as vectors in gene therapy. It was as early as 1950s that scientists first discovered that a virus can be used to inject the DNA in the cells of the host. In 1970s, various experiments started to use viruses as delivery systems for genes in the human body. In 1971, Merril, et al conducted a scientific experiment showing that DNA could be injected into the human cells to fix a biological problem in the cells. This group of scientists extracted the cells from patients suffering from a disease called Galactosemia. It is important to note that this first gene therapy experiment involves the manipulation of genes ex vivo, that is in cells growing in a petri dish outside the body in a lab, which is easier to perform than manipulating the genes inside the human body, called in vivo approach. In 1972, a famous article in the prestigious journal Science by authors Friedman and Roblin first proposed that the gene therapy may ameliorate some human genetic diseases in the future. During the 1980s, various scientists like Martin Cline and French Anderson conducted experiments on using viruses as delivery vehicles for DNA in human or mouse cells. The first human trials of gene therapy started in the late 1980s and the results were reported in early 1990s. One of the first reported clinical studies in humans involved ex vivo modification of white blood cells taken from patients with advanced melanoma, using a retroviral vector to insert a gene coding for interleurkin-2 and injecting the genetically altered cells back into the patients. During the 1990s, French Anderson reported a successful clinical trial where a retroviral vector was used to transfer a gene encoding for adenosine deaminase, ADA in children with severe combined immunodeficiency, SCID. During the 1990s, most of the work in gene therapy continued in the therapeutic area of ADA-SCID.

Despite reasonably successful clinical results, the field of gene therapy suffered a serious setback in 1999. Jesse Gelsinger, an 18-year-old patient with a disease called ornithine transcarbamylase, OTC deficiency, which results due to a missing gene coding OTC died 4 days after receiving the gene therapy in a clinical trial conducted by the University of Pennsylvania due to massive immune response resulting in multi-organ failure. As a result, FDA put a suspension on various gene therapy clinical trials.

The field of gene therapy was then suspended for almost a decade. Glybera, a gene therapy was approved in Europe for reading a genetic disease, lipoprotein lipase deficiency in 2012. However, Glybera was a commercial failure after insurers in Europe were reluctant to pay for its expensive $1 million per patient tag. Finally, uniQure (QURE) the company that developed Glybera discontinued it.

Another commercial gene therapy failure was Strimvelis, a stem cell gene therapy to treat ADA-SCID. Despite its price being lower than Glybera ($665,000 per year), the therapy was not commercially successful in Europe and was sold by GlaxoSmithKline (GSK) to Orchard Therapeutics (ORTX) in 2018. In the US, the first approved gene therapy was Kymriah, an autologous CAR-T therapy to treat autologous lymphoblastic leukemia (ALL), which was developed by Novartis (NYSE:NVS).

After Kymriah, another autologous CAR-T therapy, Yeskarta (by Kite Pharmaceuticals) was approved by FDA to treat adult diffuse large B-cell lymphoma. Kite was later acquired by Gilead (NASDAQ:GILD). The first in vivo gene therapy approval in the US was Luxturna, an AAV gene therapy for patients with RPE 65 mutation-associated retinal dystrophy, which was developed by Spark Therapeutics which also was later acquired. Luxturna was another major milestone in the history of gene therapy as it resulted in a miraculous effect of restoring vision to children who were blind since birth. Recently, bluebird bio's (BLUE) gene therapy for transfusion-dependent beta-thalassemia was approved in Europe.

The developmental landscape of gene therapies can be summarized in some excellent figures from the journal Molecular Therapy published by the American Society of Gene and Cell Therapy (ASGCT). A group of researchers reviewed the medical literature and identified 336 gene therapies being developed for 138 different clinical indications covering 165 genetic targets excluding oncology. The researchers found that 74% of these 336 gene therapies were concentrated in five medical specialties, that is, hematology, endocrinology, neurosciences, cardiology, and ophthalmology. When classifying by different disease families, inborn errors of metabolism was the disease category with a majority of ongoing gene therapy trials.

(Landscape of gene therapy programs by organ system and disease area, source: Mol. Therapy)

When looking at specific clinical indications, Duchenne muscular dystrophy (DMD) was the clinical indication with the highest number of gene therapies being developed (15). HIV gene therapies (12 gene therapy programs) and hemophilia (11 gene therapy programs) took the second and third place respectively.

In terms of the number of gene therapy/editing programs being developed by a particular company or organization, Sangamo Therapeutics (SGMO) took the top spot (see the figure below).

(Landscape of gene therapy programs by company/organization, source: Mol. Therapy)

In conclusion, gene therapy has recovered from its earlier setbacks to emerge as one of the most innovative areas in biotechnology. In this first article of the series, I have provided a brief background about gene therapy, its history, and a broad top-down landscape. In the next article in the premium service, I will discuss various delivery systems for gene therapy.

A free two-week trial for the premium Marketplace service is open for another week only. Only 25 more spots left.

Disclosure: I am/we are long BLUE, ORTX, QURE, SGMO, AXGT, CRSP. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Originally posted here:
Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy - Seeking Alpha

Discovery in Monkeys Could Lead to Treatment for Blindness-Causing Syndrome – Technology Networks

A genetic mutation that leads to a rare, but devastating blindness-causing syndrome has been discovered in monkeys for the first time. The finding offers a promising way to develop gene and cell therapies that could treat the condition in people.

Three rhesus macaques with a mutated gene that's associated with Bardet-Biedl Syndrome have been discovered, according to a study published in the journal Experimental Eye Research. It is the first known naturally occurring nonhuman primate model of the syndrome, which is also called BBS.

BBS leads to vision loss, kidney dysfunction, extra fingers or toes, and other symptoms. It occurs in 1 of 140,000 to 160,000 North American births.

"There is no cure for Bardet-Biedel Syndrome today, but having a naturally occurring animal model for the condition could help us find one in the future," said the paper's corresponding author, Martha Neuringer, Ph.D., a professor of neuroscience at the Oregon National Primate Research Center at Oregon Health & Science University, and a research associate professor of ophthalmology in the OHSU School of Medicine and OHSU Casey Eye Institute.

Broader applications

Rhesus macaques with this disease could help more than just BBS patients. BBS is part of a larger family of diseases called retinitis pigmentosa, all of which affect the retina, or the back part of the eye. A naturally occurring animal model for BBS could help researchers find treatments for a variety of retinitis pigmentosa diseases.

The discovery is timely, as gene therapy is already becoming a reality for some with retinal diseases. In the 1990s, researchers discovered dogs that had a gene mutation linked to a congenital blindness-causing condition called Leber's congenital amaurosis. That animal model played a key role in helping researchers develop what became the first FDA-approved gene therapy for an inherited disease in December 2018. Neuringer's group also hopes to develop a similar therapy for BBS.

Gene mutation

After Neuringer and colleagues discovered two related monkeys without cells that are key to vision, OHSU nonhuman primate genetics experts Betsy Ferguson, Ph.D., and Samuel Peterson, Ph.D., examined the animals' genomes. They quickly found both monkeys had a mutation of the BBS7 gene, one of at least 14 genes associated with BBS.

Because Ferguson leads an effort to genetically sequence 2,000 rhesus macaques at the nonhuman primate research center, they were also able to search the genomes of numerous other monkeys there. As a result, the team found a third monkey with the same mutation. The third rhesus macaque already had serious vision loss when it was identified in 2018 at age three and a half, although it adapted so well among its social group that the vision loss wasn't obvious. Neuringer's team is observing the third monkey over time to better understand how the disease progresses in rhesus macaques.

Neuringer and her colleagues are now using a National Eye Institute grant to breed more animals with the naturally occurring BBS7 mutation. Having more animals with the mutation can help researchers better understand the disease and test potential treatments. The knowledge they gain could enable them to develop gene and cell therapies that could cure BBS and related retinal degenerative diseases.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original:
Discovery in Monkeys Could Lead to Treatment for Blindness-Causing Syndrome - Technology Networks

Animal Stem Cell Therapy Market Revenue, Opportunity, Segment and Key Trends 2017 2025 – Health News Office

HTF MI recently introducedGlobal Hair Loss Medications Marketstudy with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2025. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players in the study areMerck, Johnson & Johnson, Gerolymatos International, Nanogen, Oxford BioLabs, Ultrax Labs, Bayer, Pharma Medico, Kirkland Signature, Phyto Ales Group, Amplixin, Keranique & DS Healthcare Group etc. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

Request Sample of Global Hair Loss Medications Market Research Report 2012-2024 @:https://www.htfmarketreport.com/sample-report/2033832-global-hair-loss-medications-market

The global Hair Loss Medications market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.

This report studies the Global Hair Loss Medications market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Global Hair Loss Medications market by companies, region, type and end-use industry.

Browse 100+ market data Tables and Figures spread through Pages and in-depth TOC on Hair Loss Medications Market by Type (, Rx & OTC), by End-Users/Application (Male, Female & Both), Organization Size, Industry, and Region Forecast to 2025. Early buyers will receive 10% customization on comprehensive study.

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2014-2018), Revenue Market Share (%) by Players (2013-2018) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/2033832-global-hair-loss-medications-market

Competitive Analysis:The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as Merck, Johnson & Johnson, Gerolymatos International, Nanogen, Oxford BioLabs, Ultrax Labs, Bayer, Pharma Medico, Kirkland Signature, Phyto Ales Group, Amplixin, Keranique & DS Healthcare Group includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.

Market Segments:The Global Hair Loss Medications Market has been divided into type, application, and region.On The Basis Of Type: , Rx & OTC.On The Basis Of Application: Male, Female & BothOn The Basis Of Region, this report is segmented into following key geographies, with production, consumption, revenue (million USD), and market share, growth rate of Hair Loss Medications in these regions, from 2014 to 2025 (forecast), covering North America (U.S. & Canada) {Market Revenue (USD Billion), Growth Analysis (%) and Opportunity Analysis} Latin America (Brazil, Mexico & Rest of Latin America) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} Middle East & Africa (GCC, South Africa, North Africa, RoMEA) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} Rest of World {Market Revenue (USD Billion), Growth Analysis (%) and Opportunity Analysis}

Buy Single User License of Global Hair Loss Medications Market Research Report 2012-2024 @https://www.htfmarketreport.com/buy-now?format=1&report=2033832

What we can offer in the Research Study The primary objective is to underline the competitive structure of Global Hair Loss MedicationsIndustry. The research includes study of several small to medium-sized companies that compete with each other and large enterprises. Identify regional factors impacting production studied at Global scale. Insights on Regulatory & Economic policies by geography giving ease to Market entry. What product features & benefits offered by Industry players studied and broken down by diverse group of customer class.

Have a look at some extracts from Table of Content

Introduction about Global Hair Loss Medications

Global Hair Loss Medications Market Size (Sales) Market Share by Type (Product Category) in 2018Hair Loss Medications Market by Application/End UsersGlobal Hair Loss Medications Sales (Volume) and Market Share Comparison by Applications(2013-2025) table defined for each application/end-users like [Male, Female & Both]Global Hair Loss Medications Sales and Growth Rate (2014-2025)Hair Loss Medications Competition by Players/Suppliers, Region, Type and ApplicationHair Loss Medications (Volume, Value and Sales Price) table defined for each geographic region defined.Global Hair Loss Medications Players/Suppliers Profiles and Sales Data

Additionally Company Basic Information, Manufacturing Base and Competitors list is being provided for each listed manufacturers

Market Sales, Revenue, Price and Gross Margin (2014-2018) table for each product type which include , Rx & OTCHair Loss Medications Manufacturing Cost AnalysisHair Loss Medications Key Raw Materials AnalysisHair Loss Medications Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain AnalysisMarket Forecast (2019-2025)..and more in complete table of Contents

Browse for Full Report at:https://www.htfmarketreport.com/reports/2033832-global-hair-loss-medications-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Read more here:
Animal Stem Cell Therapy Market Revenue, Opportunity, Segment and Key Trends 2017 2025 - Health News Office

Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) -…

CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain.

We are excited to share progress across Intellias in vivo and ex vivo programs at this important scientific venue, said Laura Sepp-Lorenzino, Ph.D., chief scientific officer, Intellia Therapeutics. Our data shows the complexity of the edits we are able to make with CRISPR/Cas9, while achieving important therapeutically relevant results. We are building on the success of our modular platform now having demonstrated consecutive targeted knockout and insertion genome edits in preclinical studies. Additionally, we presented data from our engineered cell therapy program, which continues to demonstrate the use of CRISPR/Cas9 for combined knockout and targeted integration in human T cells.

Intellia Demonstrates Consecutive In Vivo Genome Editing in Alpha-1 Antitrypsin Deficiency Mouse Model

Intellias oral presentation highlights its alpha-1 antitrypsin deficiency (AATD) study showing that consecutive dosing of two distinct lipid nanoparticle (LNP) formulations, in adultmice, achieves two targeted genome editing events, resulting in knocking out the faulty gene and restoring therapeutic levels of normal alpha-1 antitrypsin protein (hAAT). Intellias approach for AATD uses a modular hybrid delivery system combining a non-viral LNP which encapsulates CRISPR/Cas9 with an adeno-associated virus (AAV) carrying donor DNA template. Compared to traditional viral-based delivery of gene editing components, Intellias LNP delivery system can overcome the inherent limitations of immunogenicity to facilitate multiple in vivo gene editing events.

In a mouse model harboring the human PiZ allele, the most severe genetic defect in AATD patients, Intellia first reduced expression of the defective protein using gene knockout. Three weeks following the PiZ allele knockout, Intellia inserted the normal human alpha-1 antitrypsin gene, resulting in stable (throughout 12 weeks of observation), therapeutically relevant circulating protein levels. In the study, a sustained reduction of the circulating PiZ protein levels of >98% was observed for over 15 weeks. This is the first in vivo demonstration of a non-viral delivery platform, enabling a consecutive dosing approach for achieving multiple genome edits in the same tissue of the same animal. Intellias oral presentation, titled In Vivo Gene Knockout Followed by Targeted Gene Insertion Results in Simultaneous Reduced Mutant Protein Levels and Durable Transgene Expression, will be given by Anthony Forget, Ph.D., on October 25, 2019. This presentationwill be available on Intellias website at http://www.intelliatx.com.

Intellias Poster Presentations

WT1-Specific TCR Engineered Cell Therapy Studies

Intellia presented new in vitro data showing that CRISPR/Cas9-mediated genome editing for in locus insertion, combined with endogenous T Cell Receptor (TCR) knockout, leads to significant reduction in mispairing of endogenous and transferred TCR chains. This approach is expected to generate transgenic-TCR (tg-TCR) T cell therapies for hematological cancers and solid tumors. Results demonstrate a highly efficient reduction of >98% in endogenous TCR and chains while reaching >70% insertion rates of tg-TCRs without further purification. The poster titled Engineering of Highly Functional and Specific Transgenic T Cell Receptor (TCR) T Cells Using CRISPR-Mediated In Locus Insertion Combined with Endogenous TCR Knockout, was presented on October 24, 2019, by Birgit Schultes, Ph.D.

Researchers also presented in vitro data showing that a library of WT1-specific TCRs were generated, several of which Intellia is currently evaluating as part of its lead engineered cell therapy program targeting Acute Myeloid Leukemia (AML). This presentation, Generation of a Library of WT1-Specific T Cell Receptors (TCR) for TCR Gene Edited T Cell Therapy of Acute Leukemia, was presented on October 23, 2019 by Intellias collaborator, Erica Carnevale, Ph.D., IRCCS Ospedale San Raffaele.

Primary Hyperoxaluria Study

Intellia showed the continued progression of its modular platform capability using CRISPR/Cas9 to knockout either hydroxyacid oxidase 1 (Hao1) or lactate dehydrogenase A (Ldha), leading to a dose-dependent and persistent reduction of urinary oxalate levels in a Primary Hyperoxaluria Type 1 (PH1) mouse model. Data shows Ldha gene disruption also decreased LDH enzyme activity in the liver and did not impair the disposition of lactate in either wild type or renally-impaired mice. These results highlight the potential of editing genes in the glyoxylate detoxification pathway using a non-viral delivery approach as a one-time treatment option for PH1. These data were presented as a poster, titled CRISPR/Cas9-Mediated Gene Knockout to Address Primary Hyperoxaluria, by Sean Burns, M.D., on October 24, 2019.

Off-Target Screening Platform

Intellia demonstrated its approach to assess off-target activity to identify highly specific CRISPR/Cas9 guides. Results from targeted off-target sequencing in edited cells showed that biochemical off-target discovery approaches were the most sensitive and accurate. These data were presented as a poster on October 23, 2019, titled In Silico, Biochemical and Cell-Based Integrative Genomics Identifies Precise CRISPR/Cas9 Targets for Human Therapeutics, by Dan OConnell, Ph.D.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains forward-looking statements ofIntellia Therapeutics, Inc.(Intellia or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellias beliefs and expectations regarding its planned submission of an IND application for NTLA-2001 in mid-2020; its plans to generate preclinical and other data necessary to nominate a first engineered cell therapy development candidate for its AML program by the end of 2019; its plans to advance and complete preclinical studies, including non-human primate studies for its ATTR program, AML program and otherin vivoandex vivoprograms such as its AATD program; develop our proprietary LNP-AAV hybrid delivery system to advance our complex genome editing capabilities, such as gene insertion; its presentation of additional data at upcoming scientific conferences regarding CRISPR-mediated, targeted transgene insertion in the liver of NHPs, using F9 as a model gene, via the Companys proprietary LNP-AAV delivery technology, and other preclinical data by the end of 2019; the advancement and expansion of its CRISPR/Cas9 technology to develop human therapeutic products, as well as maintain and expand its related intellectual property portfolio; the ability to demonstrate its platforms modularity and replicate or apply results achieved in preclinical studies, including those in its ATTR and AML programs, in any future studies, including human clinical trials; its ability to develop otherin vivoorex vivocell therapeutics of all types, and those targeting WT1 in AML in particular, using CRISPR/Cas9 technology; the impact of its collaborations on its development programs, including but not limited to its collaboration withRegeneron Pharmaceuticals, Inc. or Ospedale San Raffaele; statements regarding the timing of regulatory filings regarding its development programs; and the ability to fund operations into the second half of 2021.

Any forward-looking statements in this press release are based on managements current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellias ability to protect and maintain our intellectual property position, including through our arbitration proceedings against Caribou; risks related to Intellias relationship with third parties, including our licensors; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of Intellias product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies will not be predictive of future results in connection with future studies; and the risk that Intellias collaborations withNovartisor Regeneron or its otherex vivocollaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellias actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Intellias most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellias other filings with theSecurities and Exchange Commission. All information in this press release is as of the date of the release, andIntellia undertakes no duty to update this information unless required by law.

Intellia Contacts:

Media:Jennifer Mound SmoterSenior Vice PresidentExternal Affairs & Communications+1 857-706-1071jenn.smoter@intelliatx.com

Investors:Lina LiAssociate DirectorInvestor Relations+1 857-706-1612lina.li@intelliatx.com

Read the original here:
Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) -...

Researchers Used Green Tea as a ‘Remote Control’ to Activate Cell Therapies for Diabetes – D-brief – Discover Magazine

(Credit: Kirasolly/Shutterstock)

Since ancient times,the health benefits of green tea have been the stuff of legend. Now,researchers are turning to the antioxidant-rich leaves for a decidedly modern purpose triggering cell-based therapies.

In a study published Wednesday in Science Translational Medicine, a team of researchers with East China Normal University and First Affiliated Hospital of Shenzhen University found that green tea can work to activate lab-made cells for disease treatment. In short, they used the beverage as a drinkable remote control.

And the authors think that the new approach, which they used as part of a successful treatment for diabetes in mice and monkeys, could one day be used to deliver remote controlled, easy-to-follow therapies for diabetes in humans.

In recent years, scientists have worked to refine how cell therapies which have shown promise in treating diseases like cancer are controlled. These therapies often rely on a chemical compound to trigger cells to secrete a specific therapeutic substance. But many of the currently-used triggers, like antibiotics, can have negative side effects or are unsafe for prolonged use.

In search of a bettertrigger, lead author Jianli Yin and her colleagues looked for a compound thatwas natural, nontoxic and perhaps even beneficial to health. Enter green tea.

In addition to itslaundry list of purported health benefits, green tea contains a molecule calledprotocatechuic acid, or PCA. The research team engineered gene switches thatcould be activated by PCA before inserting them in different human and animalcells.

To test out theirnew system, the team implanted the PCA-responsive cells into mice with diabetes,a disease that impairs the bodys ability to produce insulin. After the micewere given concentrated doses of green tea, the researchers observed that therodents insulin levels rose while their blood sugar levels fell.

But the studyauthors also noted that what works in mice doesnt always translate to humans.So, to see if they achieved the same results in our nonhuman primate cousins, thescientists tested their system on macaque monkeys, too.

The findings were indeedsimilar after drinking green tea or receiving an injection of PCA, the monkeysinsulin production returned to normal.

And while there havent yet been clinical studies on similar cell-based therapies in humans, the researchers remain optimistic that their findings could present new possibilities for disease treatment. That is, just so long as you dont mind drinking a little green tea.

Green tea has been an extremely popular beverage for more than 2,000 years, the study said. We suspect that [this system] will be considered safe and help to improve and encourage patient compliance.

Go here to see the original:
Researchers Used Green Tea as a 'Remote Control' to Activate Cell Therapies for Diabetes - D-brief - Discover Magazine

Four from Hopkins elected to National Academy of Medicine – The Hub at Johns Hopkins

ByHub staff report

Four Johns Hopkins University faculty members are among 90 new members selected to join the National Academy of Medicine, considered to be among the highest career honors for those in the fields of health and medicine. Colleen Barry, Sharon Gerecht, Elizabeth Jaffee, and Dorry Segev were selected for membership based on their outstanding professional achievement and their commitment to service.

The NAM collaborates with the National Academy of Sciences and the National Academy of Engineering to provide independent and objective analysis to the U.S. government and the international community on critical issues relating to the medical sciences, health care, and public health. New members are elected by current members through a selective process that stipulates that at least one-quarter of the organization is made up of individuals from fields outside the health professions. The newly elected members announced today bring NAM's total membership to more than 2,200 and the number of international members to approximately 180.

"These newly elected members represent the most exceptional scholars and leaders whose remarkable work has advanced science, medicine, and health in the U.S. and around the globe," said NAM President Victor J. Dzau in a message accompanying the announcement of new members. "Their expertise will be vital to addressing today's most pressing health and scientific challenges and informing the future of health and medicine for the benefit of us all. I am honored to welcome these esteemed individuals to the National Academy of Medicine."

More on the new members from Johns Hopkins:

Colleen L. Barry, professor and chair of the Department of Health Policy and Management at the Bloomberg School of Public Health, was selected for her scholarly work on developing and measuring the impact of policies that support mental health and combat addiction. She is co-director of the Bloomberg School's Center for Mental Health and Addiction Policy Research and works to show how governmental policies affect patients' access to health care and social services and the mortality rates for people with mental illness and addiction.

Sharon Gerecht is a professor in the Department of Chemical and Biomolecular Engineering at the Whiting School of Engineering and director of the Institute for NanoBioTechnology. She was recognized for her seminal studies on the interactions between stem cells and their microenvironments. She was also selected for membership for engineering artificial cell microenvironments that are capable of guiding vascular differentiation and the regeneration of tissues.

Elizabeth M. Jaffee, a professor of oncology and deputy director of the Sidney Kimmel Cancer Center, is an international leader in the development of immune based therapies for pancreatic and breast cancers. She was selected for membership to NAM on the strength of her work elucidating the complex interactions between T-cell subsets and cancer and for translating those findings into two generations of vaccine platforms.

Dorry L. Segev, professor of surgery and epidemiology and associate vice chair of the Department of Surgery at the School of Medicine, was selected for his pioneering work developing HIV-to-HIV transplants and kidney exchange. He was recognized for his contributions to the field that included initial research, a congressional bill, studies on implementation, and an examination of the national clinical impact of such transplants. His work has changed the landscape of understanding transplant risk prediction through novel big data approaches.

View original post here:
Four from Hopkins elected to National Academy of Medicine - The Hub at Johns Hopkins